Study of LY2409021 in Participants With Type 1 Diabetes
Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
This study involves taking a single dose of 100 milligrams (mg) or 300 mg LY2409021 or
placebo (an inactive medicine) taken as up to 3 capsules by mouth. The study will evaluate if
this drug will reduce the amount of insulin a type 1 diabetic needs over 24 hours. This study
includes a 7-day hospitalization period at the clinical research unit (CRU) and will involve
screening within 30 days of the start of the study as well as telephone consultations within
5 days after discharge from the CRU.